Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility

Genmab ( (GMAB) ) has shared an update.

On February 3, 2026, Genmab A/S filed a Form 6-K in the United States detailing an updated set of Articles of Association adopted on January 29, 2026, which formalize key elements of the company’s corporate structure and capital framework. The revised articles confirm the company’s current share capital of DKK 64,238,408 and grant the board authority, through March 12, 2029, to increase share capital by up to a nominal DKK 6.6 million with or without pre-emptive rights, issue warrants and convertible debt for employees and investors under specified caps, and adjust the articles accordingly, measures that collectively give management material flexibility to fund growth and incentivize staff while potentially diluting existing shareholders over time.

The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is a Danish biotechnology company based in Copenhagen that focuses on medical research, including the development, production and sale of pharmaceutical and therapeutic products, with operations structured around a share-capital model typical for listed life sciences companies.

Average Trading Volume: 1,716,454

Technical Sentiment Signal: Buy

Current Market Cap: $19.69B

Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.